# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Iovance Biotherapeutics stock up 23.2% after issuing upbeat guidance for 2024 and 2025, beating Q2 earnings expectations.
KITT: 79% | Nauticus Robotics Partners With Florida Atlantic University For Cost-Effective Aquanaut Mark 2 Testing IOVA: 38% | ...
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate ...
Piper Sandler downgraded Iovance Biotherapeutics due to a slow launch of Amtagvi (lifileucel), a skin cancer treatment. Despite...